ArticleCardiovascular drugs and therapy2025

Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.

Maeve Soto Pérez et al.PubMed ↗Publisher ↗

No numbers read from the abstract.